Chemotherapeutic management of malignant pleural effusion

Bibliography

• MONTE SA, EHYA H, LANG WR: Positive effusion cytology as the initial presentation of malignancy.Acta Cytol. (1987) 31:448–452.
   PubMed Web of Science ®Google Scholar
• LUCALLAN EC, CARR DT: Pleural effusion: a statistical study of 436 patients. N Engl. J. Med. (1955) 252:79–83.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-ARMENGOL A, RODRIGUEZ-PANADERO F: Survival and talc pleurodesis in metastatic carcinoma, revisited. A report of 125 cases. Chest (1993) 104:1482–1485.
   Google Scholar
• VAN DE MOLENGRAFT FJJM, VOOIJS GP: Survival of patients with malignancy-associated effusions. Acta Cytol. (1989) 33:911–916.
   PubMed Web of Science ®Google Scholar
• HEFFNER JE, NIETERT PJ, BARBIERI C: Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest (2000) 117:79–86.
   PubMed Web of Science ®Google Scholar
• ANTONY VB: Immunological mechanisms in pleural disease. Eur: Respir: (2003) 21:539–544.
   PubMed Web of Science ®Google Scholar
• MULLER KM: Principles of anatomy and pathology of the pleura. In: The European Respiratory Monograph: Pleural diseases. Loddenkemper R, Antony VB (Eds), European Respiratory Society Journals Ltd, (2002) 22:1–27.
   Google Scholar
• CHERNOW B, SAHN SA: Carcinomatous involvement of the pleura: an analysis of 96 patients. Am. J. Med. (1977) 63:695–702.
   PubMed Web of Science ®Google Scholar
• MEYER PC: Metastatic carcinoma of the pleura. Thorax (1966) 21:437–443.
   PubMed Web of Science ®Google Scholar
• KRAFT A, VVEINDEL K, OCHS A et al: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 85:178–187.
   PubMed Web of Science ®Google Scholar
• THICKETT DR, ARMSTRONG L, MILLAR AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax (1999) 54:707–710.
   PubMed Web of Science ®Google Scholar
• ZEBROWSKI BK, YANO S, LIU W et al: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. (1999) 5:3364–3368.
   PubMed Web of Science ®Google Scholar
• YANO S, SHINOHARA H, HERBST RS et al: Production of experimental malignant pleural effusion is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. Pathol (2000) 157:1893–1903.
   PubMed Web of Science ®Google Scholar
• PATZ EF: Malignant pleural effusions. recent advances and ambulatory sclerotherapy. Chest (1998) 113:74S–77S.
   Google Scholar
• PARULEKAR W, DI PRIMIO G, MATZINGER F, DENNIE C, BOCIEK G: Use of small-bore versus large bore chest tubes for treatment of malignant pleural effusions. Chest (2001) 120:19–25.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA AG, GRAY AW Jr, SHAHIAN DM, WILLIAMSON WA, BEAMIS JF: Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax (1994) 49:23–25.
   PubMed Web of Science ®Google Scholar
• ANTONY VB: Pathogenesis of malignant pleural effusions and talc pleurodesis. Pneumologie (1999) 53:493–498.
   PubMedGoogle Scholar
• •A good explanation of mechanism of formation of malignant effusions.
   Google Scholar
• SPEIGLER PA, HUREWITZ AN, GROTH ML: Rapid pleurodesis for malignant pleural effusions. Chest (2003) 123:1895–1898.
   PubMed Web of Science ®Google Scholar
• LORCH DG, GORDON L, WOOTEN S, COOPER IF, STRANGE C, SAHN SA: Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest (1988) 93:527–529.
   PubMed Web of Science ®Google Scholar
• DRYZER SR, ALLEN ML, STRANGE C, SAHN SA: A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest (1993) 104:1763–1766.
   PubMed Web of Science ®Google Scholar
• MAGER HJ, MAESEN B, VERZIJLBERGEN F, SCHRAMEL F: Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer (2002) 36:77–81.
   PubMed Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY: Management of malignant pleural effusions. Am. I Respir: Grit. Care Med. (2000) 162:1987–2001.
   PubMed Web of Science ®Google Scholar
• •American guidelines.
   Google Scholar
• ANTUNES G, NEVILLE E, DUFFY J, ALI N: BTS guidelines for the management of malignant pleural effusions. Thorax (2003) 58 (Suppl. 2):29–38.
   Google Scholar
• •Comprehensive British guidelines for management of pleural effusion
   Google Scholar
• MC ALPINE LG, HULKS G, THOMPSON NC: Management of recurrent malignant pleural effusion in the United Kingdom: survey of clinical practice. Thorax (1990) 45:699–701.
   PubMed Web of Science ®Google Scholar
• STRANGE C, TOMLINSON JR, WILSON C, HARLEY R, MILLER KS, SAHN SA: The histology of experimental pleural injury with tetracycline, empyema and carrageenan. Exp. MoL Pathol (1989) 51:205–219.
   PubMed Web of Science ®Google Scholar
• KROEGEL C, ANTONY VB: Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Ear: Respir. (1997) 10:2411–2418.
   PubMed Web of Science ®Google Scholar
• ANTONY VB, ROTHFUSS KJ, GODBEY SW, SPARKS JA, HOTT JW: Mechanism of tetracycline-hydrochloride induced pleurodesis. Am Rev Respir Dis. (1992) 146:1009–1013.
   PubMedGoogle Scholar
• ZALOZNIK AJ, OSWOLD SG, LANGIN M: Intrapleural tetracycline in malignant pleural effusions. Cancer (1983) 51:752–755.
   PubMed Web of Science ®Google Scholar
• EMAD A, REZAIAN GR: Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Cancer (1996) 78:2498–2501.
   Google Scholar
• MARTINEZ-MORAGON E, APARICIO J, ROGADO MC, SANCHIS J, SANCHIS F, GIL-SUAY V: Pleurodesis in malignant pleural effusions: a randomised study of tetracycline versus bleomycin. Ear: Respir. J. (1997) 10:2380–2383.
   PubMed Web of Science ®Google Scholar
• SHERMAN S, GRADY KJ, SEIDMAN JC: Clinical experience with tetracycline pleurodesis of malignant pleural effusions. South Med. J. (1987) 80:716–719.
   PubMed Web of Science ®Google Scholar
• WALKER-RENARD PB, VAUGHAN LM, SAHN SA: Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med. (1994) 120:56–64.
   PubMed Web of Science ®Google Scholar
• •An excellent review of pleurodesis agents.
   Google Scholar
• HEFFNER JE, STANDERFER RJ, TORSTVEIT J, UNRUH L: Clinical efficacy of doxycycline for pleurodesis. Chest (1994) 105:1743–1747.
   PubMed Web of Science ®Google Scholar
• PATZ EF, MCADAMS HP, ERASMUS JJ et al.: Sclerotherapy for malignant pleural effusions. A prospective randomised trial of bleomycin versus doxycycline with small-bore catheter drainage. Chest (1998) 113:1305–1311.
   Google Scholar
• KITAMURA S, SUGIYAMA Y, IZUMI T, HAYSDH R, KOSAKA K: Intrapleural doxycycline for control of malignant pleural effusion. Carr. Ther. Res. (1981) 30:515–521.
   Web of Science ®Google Scholar
• HATTA T, TSUBUOTA N, YOSHIMURA M, YANAGAWA M: Intrapleural minocycline for postoperative air leakage and control of malignant pleural effusion. Kyoto' Geka. (1990) 43:283–286.
   PubMedGoogle Scholar
• LIGHT RW, WANG NS, SASOON CS, GRUER SE, VARGAS FS: Comparison of the effectiveness of tetracycline and minocycline as sclerosing agents in rabbits. Chest (1994) 106:577–582.
   PubMed Web of Science ®Google Scholar
• SASSOON CS, LIGHT RW, VARGAS FS, GRUER SE, WANG N: Temporal Evolution of pleural fibrosis induced by intrapleural minocycline injection. Am. J. Respir. Crit. Care Med. (1994) 151:791–794.
   Web of Science ®Google Scholar
• BETHUNE N: Pleural poudrage: a new technique for the deliberate production of pleural adhesions as a preliminary to lobectomy. Thome. Surg. (1935) 4:251–261.
   Google Scholar
• KENNEDY L, VAUGHAN LM, STEED LL, SAHN SA: Sterilization of talc for pleurodesis. Available techniques, efficacy and cost analysis. Chest (1995) 107:1032–1034.
   Google Scholar
• VAN DEN HEUVEL MM, SMIT HJM, BARBIERATO SB, HAVENITH CEG, BEELEN RHJ, POSTMUS PE: Talc-induced inflammation in the pleural cavity. Eur. Respir. J. (1998) 12:1419–1423.
   PubMed Web of Science ®Google Scholar
• KENNEDY L, HARLEY RA, SAHN SA, STRANGE C: Talc slurry pleurodesis. pleural fluid and histological analysis. Chest (1995) 107:1707–1712.
   Google Scholar
• RODRIGUEZ-PANADERO F, SEGADO A, MARTIN JUAN J, AYERBE R, TORRES GARCIA I, CASTILLO J: Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am. I Respir. Crit. Care Med. (1995) 151:785–790.
   PubMed Web of Science ®Google Scholar
• CHENG DS, ROGERS J, WHEELER A,PARKER R, TEIXEIRA L, LIGHT RW: The effects of intrapleural polyclonal anti-tumor necrosis factor alpha (TNF alpha) fab fragments on pleurodesis in rabbits. Lung (2000) 178:19–29.
   PubMed Web of Science ®Google Scholar
• KENNEDY L, SAHN SA: Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest (1994) 106:1215–1222.
   PubMed Web of Science ®Google Scholar
• YIM AP, CHAN AT, LEE TW, WAN IY, HO JK: Thorascopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann. Thome. Surg. (1996) 62:1655–1658.
   PubMed Web of Science ®Google Scholar
• ZIMMER PW, HILL M, CASEY K, HARVEY E, LOW DE: Prospective randomised trial of talc slurry versus bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest (1997) 112:430–434.
   PubMed Web of Science ®Google Scholar
• ONG KC, INDUMATHI V, RAGHURAMJ, ONG YY: A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology (1999) 5:99–103.
   Google Scholar
• KUZDZAL J, STADEK K, WAS OWSKI D et al.: Talc powder versus doxycycline in the control of malignant pleural effusion: a prospective randominzed trial. Med. ScL Montt. (2003) 9:172–177.
   Google Scholar
• RINALDO JE, OWENS GR, ROGERS RIVI: Adult respiratory distress syndrome following intrapleural instillation of talc. J. Thome. Cardiovasc. Surg. (1983) 85:523–526.
   PubMed Web of Science ®Google Scholar
• BOUCHAMA A, CHASTRE J, GAUDICHET A, SOLER P, GILBERT C: Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest (1994) 86:795–797.
   Google Scholar
• BONDOC AY, BACH P, ELS NV: Talc pneumonitis: incidence, clinical features and outcome. Chest (1999) 116:358S–359S.
   Google Scholar
• SAHN S: Talc should be used for pleurodesis. Am. I Respir. Crit. Care Med. (2000) 162:2023–2024.
   PubMed Web of Science ®Google Scholar
• WEREBE EC, PAZETTI R, MILANEZ DE CAMPOS JR et al.: Systemic distribution of talc after intrapleural administration in rats. Chest (1998) 115:190–193.
   Google Scholar
• MONTES JF, FERRER J, VILLARINO MA, BAEZA B, CRESPO M, GARCIA-VALERO J: Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am. J. Respir. Crit. Care Med. (2003) 168:348–355.
   PubMed Web of Science ®Google Scholar
• FERRER J, MONTES JF, VILLARINO MA, LIGHT RW, GARCIA-VALERO J: Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest (2002) 122:1018–1027.
   PubMed Web of Science ®Google Scholar
• FRATICELLI A, ROBAGLIA-SCHLUPP A,RIERA H, MONJANEL-MOUTERDE S, CAU P, ASTOUL P: Distribution of calibrated talc after intrapleural administration. An experimental study in rats. Chest (2002) 122:1737–1741.
   Google Scholar
• ANDREWS C, GORA ML: Pleural effusions: pathophysiology and management. Ann. Pharmacother: (1994) 28:894–902.
   PubMed Web of Science ®Google Scholar
• OSTROWSKI MJ, HALSALL GM: Intracavity bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep. (1982) 66:1903–1907.
   PubMedGoogle Scholar
• RUCKDESCHEL J, MOORES D, LEE JY et al.: Intrapleural therapy for malignant pleural effusions. A randomised comparison of bleomycin and tetracycline. Chest (1991) 100:1528–1535.
   Google Scholar
• LYNCH TJ, KALISH L, MENTZER S, DECAMP M, STRAUSS G, SUGARBAKER DJ: Optimal therapy of malignant pleural effusions. Report of a randomised trial of bleomycin, tetracycline and talc and a meta analysis. Int. .1. Oncol (1996) 8:183–190.
   Google Scholar
• BITRAN JD, BROWN C, DESSER RK, KOZL OFF ME SHAPIRO C, BILLINGS AA: Intracavity bleomycin for the control of malignant effusions. J. Surg. Oncol (1981) 16:273–277.
   PubMed Web of Science ®Google Scholar
• OSTROWSKI MJ: Intracavity therapy with bleomycin for the treatment of malignant pleural effusions. J. Surg. Oncol (1989) 1 (Suppl.):7–13.
   Google Scholar
• TROTTER JM, STUART JFB, MCBETH F, MC VIE JG, CALMAN KC: The management of malignant effusions with bleomycin. Br. J. Cancer. (1979) 40:310.
   Web of Science ®Google Scholar
• AUDU PB, SING RE METTE SA, FALLAHNEJHAD M: Fatal diffuse alveolar injury following use of intrapleural bleomycin. Chest (1993) 103:1638.
   PubMed Web of Science ®Google Scholar
• GROTH G, GATZEMEIER U, HAUBINGEN K et al.: Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann. Oncol (1991) 2:213–215.
   PubMed Web of Science ®Google Scholar
• CHENG D, CHAN YM, NG TY, CHEUBG AN, NGAN HY, WONG LC: Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer. Acta Obstet. Cynecol Scand. (1999) 78:443–446.
   PubMed Web of Science ®Google Scholar
• ROSSO R, RIMOLDI R, SAL VATI F et al.: Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology (1988) 45:253–256.
   Google Scholar
• GOLDMAN CA, SKINNIDER LF, MAKSYMIUK AW: Interferon instillation for malignant pleural effusions. Ann. Oncol (1993) 4:141–145.
   PubMed Web of Science ®Google Scholar
• MASOTTI A, FUMAGALLI L, MORANDINI GC: Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with a neoplastic pleural effusion. Monaldi Arch. Chest Dis. (1997) 52:225–228.
   PubMedGoogle Scholar
• VIALLAT JR, BOUTIN C, REY F, ASTOUL P, FARISSE P, BRANDELY M: Intrapleural immunotherapy with escalating doses of interleukin -2 in non small cell lung cancer with metastatic pleural effusions. Cancer (1993) 71:4067–4071.
   PubMed Web of Science ®Google Scholar
• MEJER J, MORTENSEN KM, HANSEN H: Mepacrine hydrochloride in the treatment of malignant pleural effusion. Scand. Resp. Dis. (1977) 58:319–323.
   PubMedGoogle Scholar
• BAYLY T, KISNER D, SYBERT A, MACDONALD JS, TSOU E, SCHEIN PS: Tetracycline and quinacrine in the control of malignant pleural effusions. Cancer (1978) 41:1188–1192.
   PubMed Web of Science ®Google Scholar
• WEINGART SN, HAMLETT F, MILLER BD: Acute mental state changes following intrapleural instillation of quinacrine for traumatic pneumothorax. Psychosomatics (1996) 37:74–78.
   PubMed Web of Science ®Google Scholar
• BORDA I, KRANT M: Convulsions following intrapleural administration of quinacrine hydrochloride. JAMA (1967) 201:1049–1050.
   PubMed Web of Science ®Google Scholar
• BJORKMAN S, ELISSON LO, GABRIELSSON J: Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. J. Pharm. Pharmacol (1989) 41:160–163.
   PubMed Web of Science ®Google Scholar
• KOLDSLAND S, SVENNEVIG JL, LEHNE G, JOHNSON E: Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin. Thorax (1993) 43:790–793.
   Google Scholar
• VARGAS FS, TEIXEIRA LR, VAZ MA et al.: Silver nitrate is superior to talc slurry in producing pleurodesis in rabbits. Chest (2000) 118:808–813.
   PubMed Web of Science ®Google Scholar
• VARGAS FS, TEIXEIRA LR, ANTOLANGELO L et al: Experimental pleurodesis in rabbits induced by silver nitrate or talc. 1-Year follow-up. Chest (2000) 119:1516–1520.
   Web of Science ®Google Scholar
• OLIVARES-TORRES C, LANIADO-LABORIN R, CHAVEZ-GARCIA C, LEON-GASTELUM C, REYES-ESCAMILLA A, LIGHT RW: Iodopovidone pleurodesis for recurrent pleural effusions. Chest (2002) 122:581–583.
   PubMed Web of Science ®Google Scholar
• MILLAR JVV, HUNTER AM, HORNE NW: Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax (1979) 35:856–858.
   Web of Science ®Google Scholar
• MCLEOD DT, CALVERLEY PMA, MILLAR JW, HORNE NW: Further experience of Corynebacterium parvum in malignant pleural effusion. Thorax (1985) 40:515–518.
   PubMed Web of Science ®Google Scholar
• HILLERDAL G, KIVILOOG J, NOU E,STEINHOLTZ L: Corynebacterium parvum in malignant pleural effusion. A randomised prospective study. Earl. Respir: Dis. (1986) 69:204–206.
   Google Scholar
• BILACEROGLU S, CAGIRICI U, PERIM K, OZACAR R: Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. Monaldi Arch. Chest Dis. (1998) 53:14–22.
   PubMedGoogle Scholar
• LEAHY BC, HONEYBOURNE D, BREAR SG, CARROLL KB, THATCHER N, STRETTON TB: Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. Eurj Respir. Dis. (1985) 66:50–64.
   PubMedGoogle Scholar
• FORESTI V: Intrapleural corynebacterium parvum for recurrent malignant pleural effusions. Respiration (1995) 62:21–26.
   PubMed Web of Science ®Google Scholar
• LEE YCG, TEIXEIRA LR, DEVIN CJ et al.: Transforming growth factor-62 induces pleurodesis significantly faster than talc. Am. J. Respir: Crit. Care Med. (2001) 163:640–644.
   Google Scholar
• •A promising new agent for pleurodesis.
   Google Scholar
• LIGHT RW, CHENG DS, LEE YC, ROGERS J, DAVIDSON J, LANE KB: A single intrapleural injection of transforming growth factor-62 produces an excellent pleurodesis in rabbits. Am. J. Respir. Crit. Care Med. (2000) 162:98–104.
   PubMed Web of Science ®Google Scholar
• LEE YCG, LANE KB, PARKER RE et al:Transforming growth factor B2 produce effective pleurodesis in sheep with no systemic complications. Thorax (2000) 55:1058–1062.
   PubMed Web of Science ®Google Scholar
• LEE YCG, LANE KB, ZOIA 0, THOMPSON PJ, LIGHT RW, BLACK WELL TS: Transforming growth factor-B induces collagen synthesis without inducing IL-8 production in mesothefial cells. Eur: Respir: J. (2003) 22:197–202.
   PubMed Web of Science ®Google Scholar
• MACAULAY VM, O'BYRNE KJ, SAUNDERS MP et al.: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clinical Cancer Res. (1999) 5:513–520.
   Google Scholar
• TEIXEIRA LR, WU W, CHANG DS, LIGHT RW: The effect of corticosteroids on pleurodesis induced by doxycycfine in rabbits. Chest (2002) 121:216–219.
   PubMed Web of Science ®Google Scholar
• CANMAO X, TEIXEIRA LR, MCGOVERN JP, LIGHT RVV: Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am. Respir. Crit. Care Med. (1998) 157:1441–1444.
   PubMed Web of Science ®Google Scholar
• LEE YCG, DEVIN CJ, TEIXEIRA LR et al.: Transforming growth factor B2 induced pleurodesis is not inhibited by corticosteroids. Thorax (2001) 56:643–648.
   PubMed Web of Science ®Google Scholar
• DE GREGORIO MA, RUIZ C, ALFONSO ER, FERNANDEZ JA, MEDRANO J, ARINO I: Transcatheter intracavity fibrinolysis of loculated pleural effusions: experience in 102 patients. Cardiovasc. Intervent. Radial. (1999) 22:114–118.
   PubMed Web of Science ®Google Scholar
• JERJES-SANCHES C, RAMIREZ-RIVERA A, ELIZALDE JJ et al.: Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in haemothorax and empyema. a multicenter trial. Chest (1996) 109:1514–1519.
   PubMed Web of Science ®Google Scholar
• DAVIES CW, TRAILL ZC, GLEESON FV, DAVIES RJ: Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest (1999) 115:729-733. Affiliation Mark Weatherhead2 & George Antunest1 tAuthor for correspondence 1Consultant Respiratory Physician,The James Cook University Hospital, Marton Road, Middlesbrough, T54 3BW, UK E-mail: [email protected] Respiratory Medicine, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, UK
   Google Scholar